Bioatla Inc at HC Wainwright Investment Conference - New York(Pre Recorded) Transcript

Sep 11, 2023 / 11:00AM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst

Greetings everyone and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Arthur He, a senior biotech analyst with the firm. It's my great pleasure to have Dr. Jay Short, the Chairman, CEO, and Co-Founder of BioAtla joining us for a fireside chat.

BioAtla is a clinical-stage biopharmaceutical company, developing novel therapies for solid tumors based on its proprietary conditionally active biologics platform. The company currently has four drugs in clinic and multiple preclinical candidates across different modalities. To discuss the company's CAB technology and its development strategy in 2023 and beyond, I welcome Jay, to this fireside chat.

Good day, Jay.

Jay Short - BioAtla, Inc. - Chairman, CEO & Co-Founder

Pleasure to be here. Thank you, Arthur.

Arthur He - H.C. Wainwright & Co., LLC - Analyst

I'm so glad to see you accepting our invitation to talk to our audience today. So, first place, to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot